RYTM Rhythm Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 4, 2026
$92,83
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$74,5052 haftanın en düşüğü
$122,2052 haftanın en yükseği
Piyasa Değeri (MRQ)
$6.39B
P/E (TTM)
-29.8
Hisse Başına Kâr (TTM)
$-3.11
Gelir (TTM)
$240M
rozetleriniz
52 Haftlık Aralık
$74–$122
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$139
P/E
-29.8
ROE
-450.9%
Net Kâr Marjı
-85.6%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
RYTM Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$92.83
Piyasa Değeri (MRQ)
$6.39B
P/E (TTM)
-29.8
Hisse Başına Kâr (TTM)
$-3.11
Gelir (TTM)
$240M
ROE (TTM)
-450.9%
D/E Borç/Özsermaye (MRQ)
1.0
52 Haftlık Aralık
$75–$122
RYTM Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Rhythm Pharmaceuticals, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
sektörHealthcare
endüstriBiotechnology
çalışanlar414
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$190M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-3.112019-12-31 → 2025-12-31
Serbest Nakit Akışı$-117M2017-12-31 → 2025-12-31
Net kar marjı-85.6%2021-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | RYTM | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -29.85Y ort. ≈-15.4 | ≈-15.4 | · | · | |
| F/S (TTM) | 26.65Y ort. ≈65.8 | ≈65.8 | 25.1 | Daha pahalı | |
| F/D (MRQ) | 62.05Y ort. ≈47.3 | ≈47.3 | 18.6 | Aşırı değerli | |
| EV / EBITDA | -31.1 | · | · | · | |
| Price / FCF (Fiyat / Serbest Nakit Akışı) | -53.55Y ort. ≈-23.7 | ≈-23.7 | · | · | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -53.95Y ort. ≈-25.2 | ≈-25.2 | · | · | |
| EV / Gelir (TTM) | 25.7 | · | · | · | |
| EV / FCF | -51.1 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 65.15Y ort. ≈60.7 | ≈60.7 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | RYTM | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -83.6%5Y ort. ≈-1338.6% | ≈-1338.6% | -53.2% | Ortalamanın altında | |
| EBITDA Margin (FAVÖK Marjı) | -100.9%5Y ort. ≈-1332.3% | ≈-1332.3% | -53.2% | Ortalamanın altında | |
| Vergi Öncesi Kar Marjı (TTM) | -85.1%5Y ort. ≈-180.4% | ≈-180.4% | -55.4% | Ortalamanın altında | |
| Net Kâr Marjı (TTM) | -85.6%5Y ort. ≈-703.1% | ≈-703.1% | -69.2% | Aynı seviyede | |
| ROA (TTM) | -50.7%5Y ort. ≈-49.3% | ≈-49.3% | -20.8% | Zayıf | |
| ROE (TTM) | -450.9%5Y ort. ≈-416.2% | ≈-416.2% | -34.6% | Zayıf | |
| ROIC | -77.9%5Y ort. ≈-129.6% | ≈-129.6% | -17.1% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | RYTM | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 1.0 | · | 0.9 | Yüksek borç | |
| Cari Oran (MRQ) | 3.55Y ort. ≈5.8 | ≈5.8 | 7.3 | Düşük likidite | |
| Cari Oran (MRQ) | 3.05Y ort. ≈5.5 | ≈5.5 | 6.5 | Düşük likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.9 | · | 0.8 | Yüksek borç |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | RYTM | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 45.8%5Y ort. ≈247.7% | ≈247.7% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 100.2% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | RYTM | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.45Y ort. ≈0.2 | ≈0.2 | 0.0 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 0.95Y ort. ≈3.1 | ≈3.1 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 8.55Y ort. ≈7.3 | ≈7.3 | 8.4 | Aynı seviyede | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$458.4K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.46%
Sonraki Rapor
Kas 02, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 3, 2026 | $-0.73 | $-0.84 | 12.8% |
| 31 Mart 2026 | $-0.83 | $-0.87 | 4.6% | |
| 31 Aralık 2025 | $-0.73 | $-0.84 | 12.9% | |
| 30 Eylül 2025 | $-0.82 | $-0.74 | -11.1% | |
| 30 Haziran 2025 | $-0.75 | $-0.69 | -8.8% | |
| 31 Mart 2025 | $-0.81 | $-0.72 | -13.2% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190M | $130M | $77M | $24M | $3M | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $19M | $13M | $9M | $2M | $599.0K | · | · | · | · | · | |
| R&D Expense | $167M | $238M | $135M | $109M | $104M | $90M | $109M | $50M | $23M | $20M | |
| SG&A Expense | $195M | $144M | $118M | $92M | $68M | $46M | $37M | $28M | $10M | $6M | |
| Operating Expenses | $382M | $396M | $262M | $203M | $173M | $137M | $146M | $78M | $32M | $26M | |
| Operating Income | $-192M | $-266M | $-184M | $-179M | $-170M | $-137M | $-146M | $-78M | $-32M | $-26M | |
| Interest Expense | · | · | $14M | $5M | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | $447.0K | $3M | $5M | $4M | $566.0K | $33.0K | |
| Other Non-op | $1M | $2M | $190.0K | $-790.0K | $100M | $3M | $5M | $4M | $-1M | $33.0K | |
| Pretax Income | $-196M | $-260M | $-184M | $-181M | $-70M | · | · | · | · | · | |
| Income Tax | $497.0K | $346.0K | $564.0K | · | · | · | · | · | · | · | |
| Net Income | $-197M | $-261M | $-185M | $-181M | $-70M | $-134M | $-141M | $-74M | $-34M | $-26M | |
| EPS (Basic) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | · | · | · | |
| EPS (Diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | · | · | · | |
| Shares (Basic) | 64,984,361 | 60,995,204 | 57,673,128 | 52,120,701 | 49,600,294 | 44,127,220 | 36,422,450 | · | · | · | |
| Shares (Diluted) | 64,984,361 | 60,995,204 | 57,673,128 | 52,120,701 | 49,600,294 | 44,127,220 | 36,422,450 | · | · | · | |
| EBITDA | $-192M | $-265M | $-183M | $-178M | $-169M | $-136M | $-145M | $-78M | $-32M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $89M | $60M | $128M | $59M | $101M | $62M | $50M | $34M | $7M | |
| Short-term Investments | $335M | $231M | $216M | $206M | $236M | $72M | $230M | · | $114M | $4M | |
| Receivables | $26M | $19M | $15M | $6M | $1M | · | · | · | · | · | |
| Inventory | $26M | $19M | $9M | $3M | $111.0K | · | · | · | · | · | |
| Prepaid Expense | $26M | $16M | $9M | $12M | $12M | $9M | $10M | $7M | $3M | $638.0K | |
| Other Current Assets | $10M | $9M | $7M | $7M | $4M | $3M | $4M | $1M | $1M | $216.0K | |
| Current Assets | $467M | $374M | $308M | $354M | $308M | $182M | $302M | $259M | $151M | $11M | |
| PP&E (Net) | $1M | $632.0K | $1M | $2M | $3M | $3M | $4M | $1M | $840.0K | $930.0K | |
| PP&E (Gross) | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $2M | $1M | $1M | |
| Accum. Depreciation | $5M | $5M | $4M | $3M | $2M | $1M | $752.0K | $809.0K | $367.0K | $144.0K | |
| Intangibles | $5M | $6M | $7M | $8M | $5M | · | · | · | · | · | |
| Other Non-current Assets | $3M | $7M | $15M | $17M | · | · | · | · | · | · | |
| Total Assets | $480M | $392M | $333M | $382M | $330M | $187M | $309M | $260M | $152M | $12M | |
| Accounts Payable | $14M | $12M | $5M | $5M | $6M | $5M | $10M | $8M | $2M | $2M | |
| Accrued Liabilities | $84M | $63M | $48M | $33M | $30M | $13M | $14M | $6M | $4M | $3M | |
| Current Liabilities | $106M | $116M | $55M | $40M | $43M | $18M | $24M | $14M | $7M | $5M | |
| Capital Leases | $3M | $4M | $490.0K | $1M | $2M | · | · | · | · | · | |
| Total Liabilities | $210M | $228M | $163M | $118M | $45M | $21M | $28M | $14M | $7M | $5M | |
| Long-term Debt | $108M | $110M | · | · | · | · | · | · | · | · | |
| Total Debt | $108M | $110M | · | · | · | · | · | · | · | · | |
| Common Stock | $67.0K | $61.0K | $59.0K | $56.0K | $50.0K | $44.0K | $44.0K | $34.0K | $27.0K | $10.0K | |
| Paid-in Capital | $1.49B | $1.18B | $1.06B | $974M | $813M | $626M | $606M | $431M | $255M | $44M | |
| Retained Earnings | $-1.35B | $-1.16B | $-895M | $-710M | $-529M | $-459M | $-325M | $-185M | $-110M | $-77M | |
| AOCI | $-796.0K | $-39.0K | $134.0K | $-92.0K | $-1.0K | $49.0K | · | · | · | · | |
| Stockholders' Equity | $139M | $22M | $170M | $264M | $284M | $167M | $281M | $246M | $145M | $-33M | |
| Liabilities + Equity | $480M | $392M | $333M | $382M | $330M | $187M | $309M | $260M | $152M | $12M | |
| Shares Outstanding | 67,205,321 | 62,390,654 | 59,426,559 | 56,612,429 | 50,283,574 | 44,235,903 | 43,996,753 | 34,410,725 | 27,284,140 | 10,196,292 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $500.0K | $700.0K | $900.0K | $896.0K | $816.0K | $690.0K | $834.0K | $442.0K | $223.0K | $144.0K | |
| Stock-based Comp | $67M | $40M | $33M | $20M | $21M | $17M | $12M | $6M | $2M | $1M | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $0 | |
| Amort. of Intangibles | · | · | $855.0K | $774.0K | $342.0K | · | · | · | · | · | |
| Other Non-cash | $14M | $106M | $15M | $-13M | $-98M | $-6M | $5M | $5M | $2M | · | |
| Operating Cash Flow | $-116M | $-114M | $-136M | $-173M | $-146M | $-122M | $-123M | $-62M | $-29M | $-23M | |
| CapEx | $953.0K | $0 | $47.0K | $281.0K | $434.0K | $214.0K | $3M | $722.0K | $133.0K | $1M | |
| Investing Cash Flow | $-137M | $-48M | $-6M | $28M | $-62M | $159M | $-28M | $-87M | $-110M | $-5M | |
| Debt Issued | $0 | $0 | $24M | $72M | · | · | · | · | · | · | |
| Net Debt Issued | $-20M | $-13M | $17M | $72M | · | · | · | · | · | · | |
| Stock Issued | $34M | $39M | $49M | $131M | $162M | · | $161M | $163M | $126M | · | |
| Net Stock Activity | $34M | $39M | $49M | $131M | $162M | · | $161M | $163M | $126M | · | |
| Financing Cash Flow | $218M | $191M | $74M | $214M | $166M | $2M | $163M | $165M | $167M | · | |
| Net Change in Cash | $-35M | $29M | $-68M | $68M | $-42M | $39M | $13M | $15M | $28M | $-28M | |
| Free Cash Flow | $-117M | · | $-136M | $-174M | $-146M | $-122M | $-126M | $-63M | $-30M | · | |
| Levered FCF | · | · | $-150M | · | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% | · | · | · | · | · | |
| Net Margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | · | · | · | · | · | |
| Pretax Margin | -103.3% | -200.0% | -237.8% | · | · | · | · | · | · | · | |
| EBITDA Margin | -100.9% | -203.5% | -236.9% | -754.1% | -5366.0% | · | · | · | · | · | |
| ROA | -45.1% | -71.9% | -51.6% | -50.9% | -27.0% | -54.1% | -49.5% | -36.0% | -41.1% | · | |
| ROE | -309.1% | -1582.1% | -100.6% | -66.4% | -23.0% | -73.7% | -65.4% | -28.7% | -60.2% | · | |
| ROIC | -77.9% | -202.1% | -108.9% | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.4 | 3.2 | 5.6 | 8.9 | 7.1 | 10.1 | 12.4 | 19.0 | 22.4 | · | |
| Quick Ratio | 3.9 | 2.9 | 5.3 | 8.5 | 6.8 | 9.6 | 2.6 | 3.6 | 22.0 | · | |
| Debt / Equity | 0.8 | 5.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.7 | 5.0 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | -13.3 | -34.4 | · | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 0.9 | 1.0 | 1.6 | 1.4 | 10.8 | · | · | · | · | · | |
| Receivables Turnover | 8.5 | 7.8 | 7.3 | 6.5 | 6.2 | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.07 | $0.35 | $2.86 | $4.67 | $5.65 | $3.76 | $6.39 | $7.16 | $5.31 | · | |
| Revenue / Share | $2.92 | $2.13 | $1.34 | $0.45 | $0.06 | · | · | · | · | · | |
| Cash Flow / Share | $-1.78 | $-1.87 | $-2.36 | $-3.33 | $-2.94 | · | · | · | · | · | |
| Cash / Share | $0.81 | $1.43 | $1.01 | $2.26 | $1.18 | $2.28 | $1.42 | $1.44 | $1.25 | · | |
| EPS (TTM) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 45.8% | 68.1% | 227.6% | 649.5% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 100.2% | 245.5% | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190M | $130M | $77M | $24M | $3M | $0 | $0 | $0 | $0 | · | |
| Net Income TTM | $-197M | $-261M | $-185M | $-181M | $-70M | $-134M | $-141M | $-74M | $-34M | · | |
| Market Cap | $7.19B | $3.49B | $2.73B | $1.65B | $502M | $1.32B | $1.01B | $925M | $793M | · | |
| Enterprise Value | $6.91B | $3.28B | · | · | · | · | · | · | · | · | |
| P/E | -34.4 | -12.9 | -14.4 | -8.4 | -7.1 | -9.8 | -5.9 | · | · | · | |
| P/S | 37.9 | 26.8 | 35.3 | 69.7 | 159.1 | · | · | · | · | · | |
| P/B | 51.7 | 160.7 | 16.1 | 6.2 | 1.8 | 7.9 | 3.6 | 3.8 | 5.5 | · | |
| P / Tangible Book | 53.8 | 224.5 | 16.8 | 6.4 | 1.8 | 7.9 | · | · | · | · | |
| P / Cash Flow | -62.2 | -30.7 | -20.1 | -9.5 | -3.4 | -10.8 | -8.2 | -14.9 | -26.9 | · | |
| P / FCF | -61.7 | · | -20.1 | -9.5 | -3.4 | -10.8 | -8.0 | -14.7 | -26.8 | · | |
| EV / EBITDA | -36.1 | -12.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -59.3 | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 36.4 | 25.2 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.9% | -7.8% | -7.0% | -11.9% | -14.0% | -10.2% | -16.8% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $60M | $57M | $51M | $49M | $33M | $42M | $33M | $29M | $26M | $24M | $23M | $19M | $11M | $4M | $9M | |
| Cost of Revenue | $9M | $7M | $5M | $5M | $6M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $1M | $497.0K | $378.0K | |
| R&D Expense | $43M | $42M | $42M | $46M | $42M | $37M | $41M | $38M | $30M | $129M | $30M | $34M | $34M | $38M | $21M | $31M | |
| SG&A Expense | $67M | $64M | $57M | $52M | $46M | $39M | $38M | $35M | $36M | $34M | $32M | $30M | $30M | $25M | $22M | $22M | |
| Operating Expenses | $120M | $112M | $104M | $104M | $94M | $80M | $83M | $77M | $70M | $166M | $66M | $66M | $66M | $64M | $44M | $54M | |
| Operating Income | $-49M | $-52M | $-47M | $-53M | $-45M | $-47M | $-41M | $-44M | $-40M | $-140M | $-41M | $-44M | $-47M | $-53M | $-39M | $-45M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $3M | $3M | $3M | $2M | $46.0K | |
| Other Non-op | $1M | $-2M | $58.0K | $274.0K | $2M | $-644.0K | $325.0K | $1M | $302.0K | $524.0K | $393.0K | $-159.0K | $-17.0K | $-27.0K | $-370.0K | $-133.0K | |
| Pretax Income | $-49M | $-55M | $-48M | $-53M | $-46M | $-49M | $-43M | $-44M | $-32M | $-141M | $-41M | $-44M | $-47M | $-52M | $-41M | · | |
| Income Tax | $444.0K | $545.0K | $-31.0K | $111.0K | $337.0K | $80.0K | $-89.0K | $-344.0K | $479.0K | $300.0K | $196.0K | $368.0K | $0 | $0 | · | · | |
| Net Income | $-49M | $-56M | $-48M | $-53M | $-47M | $-49M | $-43M | $-44M | $-32M | $-141M | $-42M | $-44M | $-47M | $-52M | $-41M | $-45M | |
| EPS (Basic) | $-0.73 | $-0.83 | $-0.73 | $-0.82 | $-0.75 | $-0.81 | $-0.71 | $-0.73 | $-0.55 | $-2.35 | $-0.70 | $-0.76 | $-0.82 | $-0.92 | $-0.79 | $-0.89 | |
| EPS (Diluted) | $-0.73 | $-0.83 | $-0.73 | $-0.82 | $-0.75 | $-0.81 | $-0.71 | $-0.73 | $-0.55 | $-2.35 | $-0.70 | $-0.76 | $-0.82 | $-0.92 | $-0.79 | $-0.89 | |
| Shares (Basic) | 68,592,661 | 67,974,193 | · | 66,261,055 | 63,684,359 | 63,059,165 | · | 61,219,918 | 61,011,824 | 60,143,558 | · | 57,874,960 | 56,867,662 | 56,708,975 | 51,400,922 | 50,398,003 | |
| Shares (Diluted) | 68,592,661 | 67,974,193 | · | 66,261,055 | 63,684,359 | 63,059,165 | · | 61,219,918 | 61,011,824 | 60,143,558 | · | 57,874,960 | 56,867,662 | 56,708,975 | 51,400,922 | 50,398,003 | |
| EBITDA | · | $-52M | · | $-53M | $-45M | $-47M | · | $-44M | · | $-140M | · | $-44M | $-47M | $-53M | $-39M | $-45M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $66M | $62M | $54M | $52M | $136M | $106M | $89M | $48M | $162M | $53M | · | $65M | $116M | $110M | $185M | $113M | |
| Short-term Investments | $265M | $278M | $335M | $364M | $155M | $208M | $231M | $251M | $157M | $148M | · | $235M | $138M | $185M | $163M | $122M | |
| Receivables | $40M | $34M | $26M | $33M | $26M | $18M | $19M | $19M | $18M | $15M | · | $15M | $14M | $8M | $3M | $2M | |
| Inventory | $31M | $29M | $26M | $22M | $19M | $19M | $19M | $14M | $12M | $9M | · | $8M | $6M | $5M | · | · | |
| Prepaid Expense | $25M | $27M | $26M | $24M | $25M | $18M | $16M | $9M | $9M | $11M | · | $8M | $10M | $10M | $11M | $12M | |
| Other Current Assets | · | · | $10M | · | · | · | $9M | · | · | · | · | · | · | · | · | · | |
| Current Assets | $427M | $430M | $467M | $495M | $361M | $369M | $374M | $340M | $357M | $236M | · | $329M | $284M | $318M | $362M | $249M | |
| PP&E (Net) | $103.0K | $1M | $1M | $237.0K | $297.0K | $462.0K | $632.0K | $801.0K | $973.0K | $1M | · | $2M | $2M | $2M | $2M | $3M | |
| PP&E (Gross) | · | · | $6M | · | · | · | $5M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $5M | · | · | · | $5M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $7M | · | $7M | $7M | $8M | $8M | $8M | |
| Other Non-current Assets | · | · | $3M | · | · | · | $7M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $437M | $442M | $480M | $507M | $373M | $387M | $392M | $364M | $382M | $259M | · | $354M | $310M | $346M | $390M | $278M | |
| Accounts Payable | $16M | $12M | $14M | $14M | $16M | $12M | $12M | $5M | $5M | $8M | · | $4M | $8M | $13M | $5M | $6M | |
| Accrued Liabilities | · | · | $84M | · | · | $59M | $63M | $55M | $48M | $45M | · | $44M | $36M | $31M | $26M | $36M | |
| Current Liabilities | $124M | $103M | $106M | $104M | $129M | $112M | $116M | $98M | $55M | $54M | · | $50M | $46M | $46M | $33M | $45M | |
| Capital Leases | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $284.0K | · | $692.0K | $888.0K | $1M | $1M | $2M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | $36M | $35M | · | · | · | · | · | · | |
| Total Liabilities | $220M | $205M | $210M | $211M | $239M | $224M | $228M | $211M | $202M | $197M | · | $157M | $128M | $126M | $108M | $82M | |
| Long-term Debt | $106M | $108M | $108M | $109M | $110M | $110M | $110M | · | · | · | · | · | · | · | $73M | $34M | |
| Total Debt | · | $108M | · | $109M | $110M | $110M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $69.0K | $69.0K | $67.0K | $67.0K | $64.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $59.0K | $57.0K | $56.0K | $56.0K | $50.0K | |
| Paid-in Capital | $1.56B | $1.53B | $1.49B | $1.45B | $1.24B | $1.22B | $1.18B | $1.12B | $1.11B | $1.10B | · | $1.05B | $991M | $982M | $949M | $823M | |
| Retained Earnings | $-1.46B | $-1.41B | $-1.35B | $-1.30B | $-1.25B | $-1.20B | $-1.16B | $-1.11B | $-1.07B | $-1.04B | · | $-853M | $-809M | $-762M | $-668M | $-627M | |
| AOCI | $-912.0K | $444.0K | $-796.0K | $-926.0K | $-2M | $-51.0K | $-39.0K | $-604.0K | $-617.0K | $-181.0K | · | $-113.0K | $-14.0K | $-6.0K | $-339.0K | $-906.0K | |
| Stockholders' Equity | $103M | $123M | $139M | $149M | $-12M | $19M | $22M | $11M | $39M | $62M | $170M | $197M | $182M | $220M | $281M | $196M | |
| Liabilities + Equity | $437M | $442M | $480M | $507M | $373M | $387M | $392M | $364M | $382M | $259M | · | $354M | $310M | $346M | $390M | $278M | |
| Shares Outstanding | 68,816,868 | 68,445,084 | 67,205,321 | 66,684,077 | 63,913,185 | 63,494,892 | 62,390,654 | 61,436,251 | 61,095,949 | 60,964,468 | · | 59,089,352 | 56,896,068 | 56,852,404 | 55,756,256 | 50,454,170 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $26M | $23M | $19M | $19M | $16M | $13M | $11M | $11M | $10M | $8M | $9M | $9M | $9M | $6M | $5M | $5M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | $214.0K | $214.0K | $216.0K | |
| Operating Cash Flow | $-9M | $-44M | $-25M | $-27M | $-23M | $-40M | $-19M | $-25M | $-29M | $-41M | $-29M | $-29M | $-41M | $-36M | $-47M | $-39M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | $-1.0K | $1.0K | $0 | $47.0K | $95.0K | $60.0K | |
| Investing Cash Flow | $14M | $57M | $30M | $-246M | $54M | $25M | $21M | $-91M | $-9M | $30M | $23M | $-95M | $48M | $18M | $-40M | $36M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $38M | · | |
| Net Debt Issued | · | $-4M | · | · | · | $-5M | · | · | · | $-3M | · | · | · | $-1M | · | · | |
| Stock Issued | $0 | $0 | · | · | $0 | $34M | · | · | · | · | $0 | · | · | · | · | · | |
| Net Stock Activity | · | $0 | · | · | · | $34M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-1M | $-5M | $-3M | $189M | $-889.0K | $32M | $38M | $2M | $146M | $4M | $2M | $73M | $-965.0K | $-133.0K | $159M | $38M | |
| Net Change in Cash | $3M | $8M | $2M | $-83M | $30M | $17M | $42M | $-114M | $108M | $-7M | $-5M | $-51M | $6M | $-18M | $72M | $35M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-36M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -87.1% | · | -102.6% | -93.4% | -143.7% | · | -132.0% | · | -538.7% | · | -195.3% | -242.5% | -458.0% | · | · | |
| Net Margin | · | -92.6% | · | -103.1% | -96.1% | -151.3% | · | -131.2% | · | -544.4% | · | -196.2% | -243.0% | -455.0% | · | · | |
| Pretax Margin | · | -91.6% | · | -102.9% | -95.5% | -151.1% | · | -132.3% | · | -543.3% | · | -194.6% | · | · | · | · | |
| EBITDA Margin | · | -87.1% | · | -102.6% | -93.4% | -143.7% | · | -132.0% | · | -538.7% | · | -195.3% | -242.5% | -458.0% | · | · | |
| ROA | · | -13.4% | · | -12.2% | -12.4% | -15.3% | · | -12.2% | · | -46.8% | · | -11.9% | -15.9% | -16.6% | -11.0% | -13.5% | |
| ROE | · | -78.5% | · | -66.1% | -340.0% | -122.9% | · | -41.8% | · | -100.5% | · | -18.4% | -24.7% | -22.9% | -13.5% | -16.4% | |
| ROIC | · | -22.9% | · | -20.5% | -46.6% | -36.6% | · | -388.2% | · | -227.6% | · | -22.4% | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 4.2 | · | 4.7 | 2.8 | 3.3 | · | 3.5 | · | 4.4 | · | 6.6 | 6.2 | 6.9 | 10.9 | 5.6 | |
| Quick Ratio | · | 3.6 | · | 4.3 | 2.4 | 3.0 | · | 3.3 | · | 4.0 | · | 6.3 | 5.8 | 6.6 | 10.6 | 5.3 | |
| Debt / Equity | · | 0.9 | · | 0.7 | -9.2 | 5.8 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | · | 0.8 | · | 0.7 | -8.9 | 5.7 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -29.4 | · | -14.0 | -14.1 | -17.2 | -18.3 | · |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | 0.1 | · | 0.1 | 0.1 | 0.0 | · | · | |
| Inventory Turnover | · | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.4 | · | 0.4 | · | 0.6 | 0.7 | 0.5 | · | · | |
| Receivables Turnover | · | 2.3 | · | 2.0 | 2.2 | 2.0 | · | 2.0 | · | 2.3 | · | 2.5 | 2.5 | 2.6 | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $1.80 | · | $2.23 | $-0.19 | $0.30 | · | $0.18 | · | $1.01 | · | $3.34 | $3.20 | $3.87 | $5.04 | $3.88 | |
| Revenue / Share | · | $0.88 | · | $0.77 | $0.76 | $0.52 | · | $0.54 | · | · | · | $0.39 | $0.34 | $0.20 | · | · | |
| Cash Flow / Share | · | $-0.65 | · | · | · | $-0.64 | · | · | · | · | · | · | · | $-0.64 | · | · | |
| Cash / Share | $0.95 | $0.91 | · | $0.78 | $2.12 | $1.67 | · | $0.77 | · | $0.88 | · | $1.09 | $2.03 | $1.93 | $3.32 | $2.24 | |
| EPS (TTM) | $-3.11 | $-3.13 | · | $-3.09 | $-3.00 | $-2.80 | · | $-4.33 | $-4.48 | $-4.63 | · | · | · | · | $-3.63 | $-3.54 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $240M | $217M | · | $174M | $156M | $137M | · | $113M | $97M | $92M | · | $62M | $44M | $34M | $17M | $13M | |
| Net Income TTM | $-205M | $-203M | · | $-192M | $-183M | $-169M | · | $-259M | $-264M | $-274M | · | $-186M | $-182M | $-181M | $-181M | $-176M | |
| Market Cap | $7.64B | $5.95B | · | $6.73B | $4.04B | $3.36B | · | $3.22B | · | $2.64B | · | $1.35B | $938M | $1.01B | $1.37B | $209M | |
| Enterprise Value | $7.42B | $5.72B | · | $6.43B | $3.86B | $3.16B | · | · | · | · | · | · | · | · | · | · | |
| P/E | -35.7 | -27.8 | · | -32.7 | -21.1 | -18.9 | · | -12.1 | -9.2 | -9.4 | · | · | · | · | -6.7 | -1.2 | |
| P/S | 31.8 | 27.4 | · | 38.6 | 25.8 | 24.6 | · | 28.6 | · | 28.7 | · | 21.9 | 21.4 | 30.2 | 82.0 | 15.6 | |
| P/B | 74.2 | 48.4 | · | 45.3 | -339.2 | 177.5 | · | 287.0 | · | 42.9 | · | 6.9 | 5.1 | 4.6 | 4.9 | 1.1 | |
| P / Tangible Book | 77.9 | 50.5 | · | 47.0 | · | 259.0 | · | 666.8 | 76.6 | 48.2 | · | 7.1 | 5.4 | 4.8 | 5.0 | 1.1 | |
| P / Cash Flow | · | -134.7 | · | · | · | -83.4 | · | · | · | -64.8 | · | · | · | -27.8 | · | · | |
| EV / Revenue | 30.9 | 26.3 | · | 36.9 | 24.7 | 23.1 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.8% | -3.6% | · | -3.1% | -4.8% | -5.3% | · | -8.3% | -10.9% | -10.7% | · | · | · | · | -14.8% | -85.3% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $190M | $130M | $77M | $24M | $3M |
| Faaliyet Kâr Marjı % | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% |
| Net Gelir | $-197M | $-261M | $-185M | $-181M | $-70M |
| Seyreltilmiş Hisse Başı Kâr | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.8 | 5.1 | · | · | · |
| Cari Oran | 4.4 | 3.2 | 5.6 | 8.9 | 7.1 |
| Cari Oran | 3.9 | 2.9 | 5.3 | 8.5 | 6.8 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-117M | · | $-136M | $-174M | $-146M |
Kurumsal Sahipler (13F) 320 dosya · $8.9B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
320
Tutulan Değer
$8.9B
Yeni pozisyonlar
59
Çıkan pozisyonlar
38
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 59 (-7 önceki Ç'ye göre) | 38 (-9 önceki Ç'ye göre) | 106 (+7 önceki Ç'ye göre) | 100 (+10 önceki Ç'ye göre) | +3.0M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $740.218.912 | 6.666.837 | 8,32% | Hisse senetleri |
| BlackRock, Inc. | $683.600.828 | 6.156.902 | 7,69% | Hisse senetleri |
| VANGUARD GROUP INC | $664.816.448 | 6.210.916 | 7,48% | Hisse senetleri |
| BAKER BROS. ADVISORS LP | $622.265.747 | 5.604.483 | 7,00% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $351.837.748 | 3.168.853 | 3,96% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $348.289.452 | 3.136.895 | 3,92% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $333.753.626 | 3.005.977 | 3,75% | Hisse senetleri |
| JPMORGAN CHASE & CO | $292.178.898 | 2.652.746 | 3,29% | Hisse senetleri |
| PERCEPTIVE ADVISORS LLC | $287.156.334 | 2.586.295 | 3,23% | Hisse senetleri |
| STATE STREET CORP | $285.728.722 | 2.573.529 | 3,21% | Hisse senetleri |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $245.220.303 | 2.208.595 | 2,76% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $236.105.516 | 2.126.502 | 2,65% | Hisse senetleri |
| FEDERATED HERMES, INC. | $198.268.047 | 1.785.716 | 2,23% | Hisse senetleri |
| Polar Capital Holdings Plc | $184.713.061 | 1.663.632 | 2,08% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $170.320.392 | 1.533.698 | 1,92% | Hisse senetleri |
| Capital Research Global Investors | $170.131.602 | 1.532.303 | 1,91% | Hisse senetleri |
| CITADEL ADVISORS LLC | $140.303.282 | 1.263.652 | 1,58% | Hisse senetleri |
| Checkpoint Capital L.P. | $131.681.580 | 1.186.000 | 1,48% | Hisse senetleri |
| Siren, L.L.C. | $126.160.613 | 1.136.275 | 1,42% | Hisse senetleri |
| MORGAN STANLEY | $123.492.178 | 1.112.240 | 1,39% | Hisse senetleri |
| FMR LLC | $113.899.059 | 1.025.840 | 1,28% | Hisse senetleri |
| Pictet Asset Management Holding SA | $106.252.095 | 957.785 | 1,19% | Hisse senetleri |
| Woodline Partners LP | $84.259.668 | 758.891 | 0,95% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $79.886.248 | 918.153 | 0,90% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $77.814.059 | 894.723 | 0,87% | Hisse senetleri |
| Clearbridge Investments, LLC | $77.329.368 | 696.473 | 0,87% | Hisse senetleri |
| Rock Springs Capital Management LP | $76.899.156 | 692.598 | 0,86% | Hisse senetleri |
| NORGES BANK | $76.149.259 | 685.844 | 0,86% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $64.067.973 | 577.033 | 0,72% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $61.370.500 | 552.738 | 0,69% | Hisse senetleri |
| Integral Health Asset Management, LLC | $61.066.500 | 550.000 | 0,69% | Hisse senetleri |
| Invesco Ltd. | $60.319.379 | 543.271 | 0,68% | Hisse senetleri |
| NORTHERN TRUST CORP | $59.993.061 | 540.332 | 0,67% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $54.265.580 | 488.747 | 0,61% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $49.488.625 | 445.723 | 0,56% | Hisse senetleri |
| LOOMIS SAYLES & CO L P | $48.198.345 | 434.102 | 0,54% | Hisse senetleri |
| Candriam S.C.A. | $48.032.508 | 433.025 | 0,54% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $47.089.907 | 541.450 | 0,53% | Hisse senetleri |
| Squarepoint Ops LLC | $46.956.919 | 422.921 | 0,53% | Hisse senetleri |
| Point72 Asset Management, L.P. | $45.989.736 | 414.210 | 0,52% | Hisse senetleri |
| Sofinnova Investments, Inc. | $45.303.238 | 408.027 | 0,51% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $44.593.674 | 401.634 | 0,50% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $44.078.910 | 397.000 | 0,50% | Hisse senetleri |
| Bank of New York Mellon Corp | $43.750.776 | 394.044 | 0,49% | Hisse senetleri |
| BRAIDWELL LP | $42.316.642 | 381.128 | 0,48% | Hisse senetleri |
| Artisan Partners Limited Partnership | $39.395.220 | 354.816 | 0,44% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $36.136.934 | 325.470 | 0,41% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $35.851.587 | 322.900 | 0,40% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $35.165.311 | 316.719 | 0,40% | Hisse senetleri |
| SILVERARC CAPITAL MANAGEMENT, LLC | $34.581.515 | 311.461 | 0,39% | Hisse senetleri |
Aktivistler ve %5+ sahipler 7 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| 30 Nisan 2024 | · | İlk başvuru | · | SEC | |
| Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd., C2 Life Sciences LLC, Perceptive Discovery Fund LP, Joseph Edelman ×3 başvurular | 17 Nisan 2024 | · | İlk başvuru | · | SEC |
| New Enterprise Associates 13, L.P., NEA Partners 13, L.P., NEA 13 GP, LTD, Forest Baskett, Patrick J. Kerins, Scott D. Sandell ×2 başvurular | 29 Mart 2023 | · | İlk başvuru | Pasif yatırım | SEC |
| MPM BioVentures V, L.P., MPM Asset Management Investors BV5 LLC, MPM BioVentures V GP LLC, MPM BioVentures V LLC, Ansbert Gadicke, Luke Evnin, Todd Foley ×2 başvurular | 26 Haziran 2020 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 05 Şubat 2020 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 12 Şubat 2019 | · | İlk başvuru | Pasif yatırım | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP V LLC ×5 başvurular | 10 Ağustos 2018 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 37 içeriden öğrenenler · 16 yöneticiler · 12 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| David P Meeker | President and CEO | 14 Eylül 2026 M | 239.258 | 0 | 5 | $-5.133.559 |
| Keith Michael Gottesdiener | CEO & President | 09 Mart 2020 M | 558.250 | 0 | 0 | $0 |
| Hunter C Smith | Chief Financial Officer | 31 Ağustos 2026 M | 114.024 | 0 | 26 | $-8.837.032 |
| Manher Joshi | Chief Medical Officer | 17 Ağustos 2026 A | · | 0 | 0 | $0 |
| Alastair Garfield | Chief Scientific Officer | 13 Ağustos 2026 S | 2.295 | 0 | 4 | $-912.697 |
| Joseph Shulman | Chief Technical Officer | 13 Ağustos 2026 M | 15.915 | 0 | 6 | $-3.672.703 |
| Jennifer Chien | EVP, Head of North America | 13 Ağustos 2026 M | 0 | 0 | 1 | $-8.901.395 |
| Yann Mazabraud | EVP, Head of International | 12 Ağustos 2026 M | 55.655 | 0 | 6 | $-6.620.591 |
| Christopher Paul German | Corporate Controller & CAO | 15 Mayıs 2026 M | 0 | 0 | 2 | $-930.921 |
| Pamela J. Cramer | Chief Human Resources Officer | 11 Şubat 2026 A | 29.376 | 0 | 4 | $-2.987.366 |
| William T. Roberts | Chief Accounting Officer | 29 Mart 2023 M | 7.872 | 0 | 0 | $0 |
| Linda Shapiro Manning | Chief Medical Officer | 09 Şubat 2022 A | · | 0 | 0 | $0 |
| Murray Stewart | Chief Medical Officer | 11 Şubat 2021 A | · | 0 | 0 | $0 |
| Nithya Desikan | Chief Commercial Officer | 31 Ağustos 2020 M | 43.602 | 0 | 0 | $0 |
| Leonardus H.T. Van Der Ploeg | Chief Scientific Officer | 31 Mayıs 2019 M | 42.339 | 0 | 0 | $0 |
| Fred T. Fiedorek | Chief Medical Officer | 14 Şubat 2018 A | · | 0 | 0 | $0 |
| Lynn A. Tetrault | Yönetim kurulu üyesi | 24 Haziran 2026 A | 11.712 | 0 | 1 | $-3.711.840 |
| Stuart A Arbuckle | Yönetim kurulu üyesi | 24 Haziran 2026 A | 11.712 | 0 | 0 | $0 |
| Christophe Jean | Yönetim kurulu üyesi | 24 Haziran 2026 A | 11.712 | 0 | 0 | $0 |
| Jennifer L Good | Yönetim kurulu üyesi | 24 Haziran 2026 A | 11.712 | 0 | 0 | $0 |
| David W J Mcgirr | Yönetim kurulu üyesi | 24 Haziran 2026 A | 11.712 | 0 | 0 | $0 |
| Kimberly J Popovits | Yönetim kurulu üyesi | 01 Nisan 2026 A | · | 0 | 0 | $0 |
| Edward T. Mathers | Yönetim kurulu üyesi | 12 Mart 2026 J | 14.168 | 0 | 0 | $0 |
| Camille L Bedrosian | Yönetim kurulu üyesi | 24 Haziran 2025 A | 7.000 | 0 | 0 | $0 |
| Todd Foley | Yönetim kurulu üyesi | 15 Mart 2021 S | 909.258 | 0 | 0 | $0 |
| Neil Exter | Yönetim kurulu üyesi | 06 Haziran 2018 A | 0 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% sahip | 10 Ekim 2017 C | 545.256 | 0 | 0 | $0 |
| Ravi Viswanathan | 10% sahip | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
| Ipsen, S.A. | 10% sahip | 10 Ekim 2017 C | 833.099 | 0 | 0 | $0 |
| Forest Baskett | 10% sahip | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
| Patrick J. Kerins | 10% sahip | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
| David M Mott | 10% sahip | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
| James M Barrett | 10% sahip | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
| Peter J Barris | 10% sahip | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
| Pfizer Inc. | 10% sahip | 10 Ekim 2017 C | 1.427.639 | 0 | 0 | $0 |
| Simon Kelner | · | 11 Şubat 2021 A | · | 0 | 0 | $0 |
| Scott D. Sandell | · | 10 Ekim 2017 C | 4.909.956 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 35 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| MEDI · Harbor ETF Trust | 4,02% | 16.680 NS | 31 Temmuz 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,55% | 15.357 NS | 31 Temmuz 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,79% | 39.370 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,59% | 25.494 SH | 02 Ekim 2026 | Günlük |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,57% | 33.067 NS | 31 Temmuz 2026 | N-PORT |
| IBB · iShares Trust | 0,50% | 507.659 SH | 11 Eylül 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,43% | 4.873 SH | 02 Ekim 2026 | Günlük |
| IWO · iShares Trust | 0,37% | 517.925 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,36% | 59.038 SH | 19 Ağustos 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,22% | 538 NS | 31 Temmuz 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,22% | 1.927 NS | 31 Temmuz 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,21% | 908.106 SH | 19 Ağustos 2026 | Günlük |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 14.383 NS | 31 Temmuz 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,20% | 27.831 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,19% | 317.548 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,18% | 1.410.048 SH | 11 Eylül 2026 | Günlük |
| ISCG · iShares Trust | 0,18% | 16.741 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,18% | 26.425 NS | 31 Temmuz 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,17% | 9.930 NS | 31 Temmuz 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,09% | 1.571.929 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,09% | 164.403 SH | 19 Ağustos 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 715.506 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,08% | 25.957 NS | 31 Temmuz 2026 | N-PORT |
| WSML · iShares Trust | 0,05% | 3.457 SH | 11 Eylül 2026 | Günlük |
| ESML · iShares Trust | 0,05% | 14.054 SH | 11 Eylül 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 12.237 SH | 02 Ekim 2026 | Günlük |
| TILT · FlexShares Trust | 0,01% | 3.058 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.177.236 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 4.502 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,01% | 12.173 SH | 19 Ağustos 2026 | Günlük |
| ITOT · iShares Trust | 0,01% | 83.940 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,01% | 14.197 SH | 11 Eylül 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 43.280 SH | 19 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 2.395 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 49.815 SH | 11 Eylül 2026 | Günlük |
RYTM Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 23 analist
AL
Medyan hedef
$143.00
+54,0%
8 34,8%
Güçlü Al
12 52,2%
Al
3 13,0%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
17 analist · 2026-09-29Ortalama hedef $138.59 +49,3%
← Tüm hedeflerin altında
Mevcut fiyat $92.83
Düşük$105.00
Ortalama$138.59
Yüksek$160.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| RYTM | $7.19B | -34.4 | 45.8% | -103.6% | -309.1% | · |
| IMVT | $5.07B | -9.0 | 229.2% | · | -73.7% | · |
| IOVA | $1.12B | -2.5 | 60.6% | -148.4% | -56.0% | · |
| GRAL | $3.45B | -7.7 | 17.2% | -277.5% | -16.7% | · |
| CGON | $3.35B | -20.0 | 254.7% | -3985.0% | -22.6% | · |
| KOD | $1.73B | -6.5 | · | · | -202.0% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
Son Haberler Bu şirketten bahseden son manşetler
Rhythm Pharmaceuticals Hissesinin Salı günü Neden Zafer Kazandığını
Nasdaq · 4 ay, 4 hafta önce
Rhythm Pharmaceuticals, Inc. (RYTM) Şu Anda İyi Bir Hisse Senedi mi?
Yahoo Finance · 5 ay, 1 hafta önce
Ritım, Yeni Bir Obezite Onayı Ele Geçiriyor; Lilly ve Novo'nun "Düşüş Yaşadığı" Yerde Nasıl İlerledi
Yahoo Finance · 6 ay, 1 hafta önce
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 4, 2026